INHIBIKASE THERAPEUTICS INC (IKT)
Health Care · Clinical-stage biopharmaceuticals / pulmonary hypertension therapeutics · NASDAQ
A pre-revenue biotech company developing IKT-001, a novel therapeutic targeting pulmonary arterial hypertension, currently in Phase 3 clinical trials with no approved products or operating revenue.
What INHIBIKASE THERAPEUTICS INC does
Inhibikase Therapeutics is a clinical-stage biopharmaceutical company focused on the development of IKT-001, a novel therapeutic candidate for treating pulmonary arterial hypertension (PAH). The company is currently conducting Phase 3 clinical trials (the IMPRES study) to support regulatory approval and potential commercialization of IKT-001. With no approved products, no commercial revenue, and limited operating history, Inhibikase is entirely dependent on raising capital to fund its drug development activities and the completion of clinical trials.
Themes: ["PAH / pulmonary arterial hypertension","clinical-stage drug development","cardiovascular therapeutics"]
Fundamentals
- Price$2.04 as of 2026-07-09 close
- Market cap$269M as of 2026-07-10
- 1-year return+1.0% as of 2026-07-09 close
- Net margin-5981.3% as of 2026-07-10
- ROE-57.1% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Beta0.97 as of 2026-07-10
Key risks (from latest filing)
["Clinical-stage company with no approved products, no revenue, and dependence on successful completion of Phase 3 trials; failure to demonstrate efficacy or safety in the IMPRES study could prevent regulatory approval and destroy company viability","Substantial capital requirements to complete Phase 3 development and potential commercialization; inability to raise additional funding on acceptable terms could halt clinical trials and threaten long-term viability","Regulatory approval is uncertain and time-consuming; the FDA may reject the application, request additional studies, or impose unfavorable conditions that could delay or prevent commercialization of IKT-001"]
Competitors & peers
- Actelion (acquired by Johnson & Johnson)
- Gilead Sciences (PAH portfolio)
- United Therapeutics
- Reata Pharmaceuticals
- Gossamer Bio
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.